Main uses of Lactulose AL

Lactulose AL is primarily used as a laxative to address specific digestive and metabolic conditions. As a synthetic sugar derivative, it functions by reaching the colon mostly unchanged, where it is broken down by intestinal bacteria into organic acids.

Treatment of Constipation

The most common application of Lactulose AL is the treatment of constipation. It is categorized as an osmotic laxative. By increasing the concentration of solutes in the bowel, it draws water into the intestinal lumen. This process leads to:

• An increase in stool volume.
• A softening of the stool consistency.
• Stimulation of natural intestinal movement (peristalsis).

These effects facilitate easier bowel movements in cases where dietary changes or increased fiber intake have not been sufficient.

Management of Portal Systemic Encephalopathy

Lactulose AL is also used in the management of portal systemic encephalopathy, a brain dysfunction caused by severe liver disease. In patients with impaired liver function, nitrogenous waste products such as ammonia can build up in the bloodstream and affect the central nervous system.

Lactulose AL helps lower blood ammonia levels through several mechanisms:

• Acidification: It lowers the pH level in the colon, which converts ammonia into ammonium. Ammonium is less easily absorbed back into the bloodstream.
• Migration: The acidic environment encourages ammonia to move from the blood into the gut.
• Elimination: The laxative effect ensures that these waste products are expelled from the body more quickly.

Benefits for Intestinal Health

In addition to its primary uses, Lactulose AL acts as a prebiotic. By serving as a food source for beneficial intestinal bacteria, such as Bifidobacteria and Lactobacilli, it supports a balanced internal environment. This shift in the intestinal flora contributes to the overall effectiveness of the treatment by maintaining the acidic environment necessary for its metabolic functions.

Regulatory References

1. Lactulose is used as a laxative in the treatment of chronic constipation

Who Can and Cannot Use Lactulose AL? - Eligibility Summary

This section summarizes the official populations for whom the use of Lactulose AL is either restricted or prohibited, based on regulatory labeling information. Lactulose AL is strictly contraindicated (must not be used) in patients with:

• Galactosaemia or a required low galactose diet.
• Known hypersensitivity (allergy) to lactulose or any of its inactive ingredients.
• Gastrointestinal obstruction (bowel blockage) or perforation (a hole in the GI tract).
• Acute inflammatory bowel diseases, such as severe ulcerative colitis or Crohn's disease.

Special Considerations and Restricted Use

Use of Lactulose AL requires caution and should be discussed with a healthcare professional in the following groups:

• Infants and small children: Use is generally reserved for special circumstances and requires medical supervision.
• Patients with diabetes: Due to the small amounts of absorbable sugars (galactose and lactose) in the product, monitoring is recommended.
• Pregnancy and Breast-feeding: While it is generally considered acceptable, use should occur only if clearly needed and if the potential benefit outweighs any theoretical risk.
• Unexplained abdominal pain: The cause of the pain should be determined before starting treatment.

Interactions with other medicines and products

Interaction Scope

• Medicinal product categories with documented interactions: Non-absorbable antacids, oral anti-infective agents, other laxatives, diuretics (thiazides, Amphotericin B), steroids, cardiac glycosides.
• Specific interacting medicines (if explicitly listed): Neomycin.
• Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interference with colonic bacterial degradation of Lactulose or pharmacodynamic effects that increase potassium loss.
• Timing-based interaction rules (if applicable): Co-administration of other laxatives must be avoided during the initial phase of therapy for portal-systemic encephalopathy (PSE).
• Population-specific interaction notes (if applicable): The use of other laxatives is restricted for patients with PSE. Caution is advised for patients prone to electrolyte disorders.
• Interaction-related restrictions: A theoretical hazard exists during electrocautery procedures (proctoscopy or colonoscopy). This requires a thorough bowel cleansing with a non-fermentable solution to mitigate the risk of an explosive reaction.

---

Interaction Classifications (High-Level)

• Interaction severity classification (as defined in official documents): Lack of desired treatment effect; Interference with therapeutic monitoring; Increased risk of adverse effect.
• Regulatory basis: U.S. Food and Drug Administration (FDA) and European Summary of Product Characteristics (SmPC).

---

Official interaction structure

The regulatory profile centers on pharmacodynamic interactions that affect either the therapeutic environment or patient electrolyte status. Non-absorbable antacids and oral anti-infective agents may compromise the colonic pH drop, potentially resulting in a lack of treatment effect. Co-administration with diuretics (like thiazides) or steroids may increase the loss of potassium, and this electrolyte imbalance may enhance the effect of cardiac glycosides. The restriction on using other laxatives in PSE patients is necessary to prevent the resulting loose stools from hindering the individualized drug dose determination.

The action of Lactulose is initiated by a sequence of biochemical events localized to the large intestine. The synthetic disaccharide is not cleaved by human enzymes and thus acts as an exclusive substrate for saccharolytic colonic bacteria (e.g., Lactobacilli).

Colonic Fermentation and Fluid Modulation

The bacterial breakdown of Lactulose produces short-chain organic acids (like lactic and acetic acid). This accumulation of osmotically active molecules significantly increases the intraluminal osmotic pressure, drawing water from the body into the colon. This fluid influx increases stool volume and hydration, which, along with the acidic metabolites, mechanically and chemically stimulates peristaltic motility, thereby modulating the colonic transit rate.

Acid-Dependent Ionic Trapping

The production of these organic acids causes a critical, localized drop in colonic pH. This acidification creates the required chemical environment for ionic trapping, where the systemic metabolite NH3 (ammonia) is converted into its charged, non-absorbable form, ammonium ( NH4^+). This conversion and trapping facilitates a reduction in the reabsorption of ammonia into the portal circulation and contributes to the removal of nitrogenous waste through increased fecal excretion of the ammonium ion ( NH4^+).

How to Use Lactulose AL: Official Administration Guidelines

Lactulose AL is administered following distinct protocols that depend on the specific condition being managed. The medicine is primarily available for oral administration as a solution or powder for solution. For the acute management of severe liver conditions, it may also be administered via the rectal route as a retention enema.

---

Official Dosing and Frequency

Condition	Starting Adult Dosing Regimen	Frequency Pattern
Chronic Constipation	15 mL to 45 mL (10 g to 30 g)	Once daily or in two divided doses
Hepatic Encephalopathy (HE)	30 mL to 50 mL (20 g to 33 g)	Three to four times daily

---

Administration and Procedural Rules

For oral intake, the solution may be administered undiluted or mixed with water, fruit juice, or milk to improve acceptability. For a once-daily dose, taking the medication at the same time each day, often with breakfast, is suggested. Adequate daily fluid intake (e.g., 1.5 L to 2 L) is formally advised during the course of therapy.

For HE, the dosage is adjusted to achieve a specific endpoint of two to three soft stools daily, and the effect may take 24 to 48 hours to be observed. Rectal administration is generally continued only until the patient's condition is stable enough to permit a switch to the oral regimen. Furthermore, for long-term use in older adults, periodic monitoring of serum electrolytes is indicated.

Research Evidence / Overview of Studies for Lactulose AL

Evidence for Use in Chronic Constipation

Research has examined the use of this medicine in conditions of persistent irregularity through Randomized Controlled Trials (RCTs). These studies explored monitoring outcomes related to physical discomfort, such as changes in stool frequency and consistency. Findings describe patterns observed where stool frequency was greater in participants receiving the medicine compared to those receiving a placebo. However, long-term patterns of use for constipation are not fully established, as follow-up durations were limited (typically 6 to 12 weeks).

Evidence for Use in Hepatic Encephalopathy (HE)

This medicine was evaluated in settings involving systemic or functional imbalance, specifically Hepatic Encephalopathy (HE). The evidence base for this use has been assigned an Evidence Level of High by regulatory bodies, reflecting a substantial history of RCTs. Studies monitored endpoints such as shifts in symptom scoring and recurrence rates. For prevention studies, recurrence rates were observed to be less frequent in the group receiving the medicine. Research was associated with ethical constraints that limit new large-scale placebo trials, given its status as a standard intervention.

Evidence in Specific Patient Populations and Research Gaps

Research has examined the use of this medicine across different patient groups, including specific trials for children with constipation. For HE, studies focus almost exclusively on adult patients with cirrhosis. While this provides a strong foundation, data for certain groups remain insufficient. The overall evidence quality for constipation is considered moderate due to study heterogeneity and limited follow-up, contrasting with the High level for HE. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Common questions about Lactulose AL (FAQ)

Q: What is Lactulose AL used for?

Lactulose AL is primarily indicated for the treatment of constipation. It may also be used to treat or prevent a certain brain problem that occurs due to severe liver disease.

Q: How does Lactulose AL work to relieve constipation?

It is a type of synthetic sugar that is not digested in the small intestine. Instead, it moves to the large intestine where it is broken down by bacteria, which may draw water into the colon. This action may help soften stools and support more regular bowel movements.

Q: When is the best time to take Lactulose AL?

The product label generally recommends that the timing of administration should align with a patient's individual needs and the prescribing healthcare provider’s instructions. It may be taken with or without food.

Q: Are there any common side effects?

As with many medications, some people may experience side effects. Commonly reported effects related to Lactulose AL include mild bloating, stomach pain, and gas. These effects are often temporary as the body adjusts to the medication.

Q: Can I stop taking Lactulose AL once my constipation improves?

Decisions about stopping or changing the use of any medication, including Lactulose AL, should be made in consultation with a qualified healthcare professional. Your provider can offer guidance based on your specific health condition and needs.

How to Store and Dispose of Lactulose AL

Storage Temperature and Protection

Lactulose solution must be stored at a controlled room temperature between 20°C and 25°C (68°F and 77°F). It is mandatory to avoid freezing and prolonged exposure to temperatures above 30°C (86°F), which may cause the product to become turbid or extremely dark. The container should be kept tightly closed and away from direct light.

Container and Child Safety

The medication must be kept in the container it came in and stored out of the sight and reach of children. The container should use a child-resistant closure.

Disposal

Unused or expired Lactulose solution and containers must be disposed of in accordance with local requirements for pharmaceutical waste. Consult a healthcare professional or local authority for information on drug take-back programs.